Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Winston-Salem, North Carolina 27157


Purpose:

RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.


Study summary:

OBJECTIVES: - To determine if patients with cancer can exercise safely and routinely, under supervision, while receiving anthracycline chemotherapy. - To determine the magnitude of the change in the peak ventilatory oxygen uptake (VO2) before and after completion of anthracycline chemotherapy with concurrent exercise versus without exercise in patients with cancer. OUTLINE: Patients are randomized to 1 of 2 intervention arms. - Arm I (exercise): Patients undergo supervised aerobic exercise (walk or bicycle) 3 days a week concurrently with standard anthracycline-based chemotherapy for approximately 18-24 weeks. - Arm II (non-exercise): Patients receive standard anthracycline-based chemotherapy for approximately 18-24 weeks. Patients undergo peak ventilatory oxygen uptake (VO_2) by exercise bike test with gas exchange analysis at baseline and at 2 weeks after completion of anthracycline-based chemotherapy.


Criteria:

DISEASE CHARACTERISTICS: - Patients with cancer scheduled to receive 4-6 courses of an anthracycline-based chemotherapy PATIENT CHARACTERISTICS: - Able to pedal a stationary bicycle - No severe hypertension (systolic blood pressure > 220 mm Hg or diastolic blood pressure >120 mm Hg) - No atrial fibrillation with an uncontrolled ventricular response - No ventricular arrhythmias - No unstable angina - No acute myocardial infarction within the past 28 days of enrollment - No severe valvular heart disease - No severe (exercise-limiting) peripheral vascular disease - No severe pulmonary disease PRIOR CONCURRENT THERAPY: - See Disease Characteristics


NCT ID:

NCT00728429


Primary Contact:

Principal Investigator
Gretchen Wells, MD, PhD
Comprehensive Cancer Center of Wake Forest University


Backup Contact:

N/A


Location Contact:

Winston-Salem, North Carolina 27157
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 23, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.